

**Supplementary Table 1. Chemotherapy regimens given to patients**

<b>Regimen</b>	<b>Patients with Thymoma</b>	<b>Patients with Thymic Carcinoma</b>
Cisplatin, Adriamycin, cyclophosphamide	36 (59)	2 (13)
No induction therapy	8 (13)	4 (27)
Carboplatin, paclitaxel	5 (8)	4 (27)
Cisplatin, etoposide	6 (8)	1 (7)
Cisplatin, docetaxel	—	2 (13)
Other	6 (10)	—

Data are no. (%).

**Supplementary Table 2. Histologic subtypes (N = 72)**

<b>Histologic Subtype</b>	<b>No. (%)</b>
AB	1 (1)
B1	11 (15)
B2	20 (28)
B2/B3	2 (3)
B3	15 (21)
Cortical	2 (3)
Epithelial type	1 (1)
Lymphoepithelial-like features	2 (3)
Squamous cell carcinoma or thymic carcinoma	14 (19)
Type 1	2 (3)
Type 3	1 (1)
Type A with foci of thymic carcinoma	1 (1)